Blogs (5)

RLA-5331 is an Iron Activator Containing Anti-androgen

RLA-5331 is an iron activator containing anti-androgen. RLA-5331 is used for metastatic castrated tolerant prostate cancer (mCRPC) research.
Xentuzumab is a Monoclonal Antibody That Targets IGF Ligands IGF1 and IGF2

Xentuzumab is an anti-IGF-1/2 mAb, also targets to INSR-A. Xentuzumab inhibits tumor proliferation and induces apoptosis.
Proxalutamide (GT0918) is a Potent Androgen Receptor (AR) Antagonist

Proxalutamide (GT0918) is an orally active potent androgen receptor (AR) antagonist. And Proxalutamide (GT0918) plays important roles in the study of prostate cancer and COVID-19.
IPI-9119 is an Orally Active, Selective and Irreversible FASN Inhibitor

IPI-9119 is an orally active, selective and irreversible FASN inhibitor with potent anti-cancer activity. IPI-9119 induces cell cycle arrest, apoptosis.
Y06137 is a Selective BET Inhibitor for Treatment of CRPC

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.